KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study).

Kazuto Nishio, Kazuko Sakai, Makoto Nishio, Takashi Seto, Carla Visseren-Grul, Michelle Carlsen, Sotaro Enatsu, Tomoko Matsui, Kazuhiko Nakagawa

JTO Clin Res Rep 7(5) 100963

PMID42006277
PMCIDPMC13091193
DOI10.1016/j.jtocrr.2026.100963
发表日期2026-04-20
摘要

摘要

INTRODUCTION: A previous analysis of the RELAY phase 3 liquid biopsy addendum demonstrated suppressed EGFR-activating mutation allele count, increased total cell-free DNA (cfDNA) concentration, and shortened cfDNA fragment size with ramucirumab (RAM) plus erlotinib (ERL) versus placebo (PL) plus ERL in patients with EGFR-mutated NSCLC. We report updated data by EGFR mutation subtypes. METHODS: Patients were randomized 1:1 to RAM plus ERL or PL plus ERL. Liquid biopsy samples were collected at baseline, during treatment, and at post-progression 30-day follow-up. EGFR-activating mutation allele count, plasma cfDNA concentration, cfDNA fragment size, and treatment-emergent T790M were analyzed in patients with a valid baseline sample (N = 131) by EGFR mutation subgroups (ex19del; L858R). RESULTS: Within both ex19del and L858R subgroups, EGFR-activating mutation allele count decreased from baseline to cycle 4 in both treatment arms. Total cfDNA concentration significantly increased from baseline to cycle 4 (p < 0.0001) and was sustained to follow-up in the RAM plus ERL arm within the L858R subgroup only. cfDNA fragment size decreased from baseline to cycle 4 in the RAM plus ERL arm within both subgroups. T790M rates in the RAM plus ERL and PL plus ERL arms were 22.2% (four of 18) and 52.9% (nine of 17), respectively, in the ex19del subgroup by cycle less than or equal to 155 and 31.8% (seven of 22) and 18.8% (three of 16), respectively, in the L858R subgroup by cycle less than or equal to 176. CONCLUSIONS: This updated analysis revealed differences in total cfDNA concentration and T790M mutation rates between ex19del and L858R. RAM plus ERL may exhibit greater antitumor effects on L858R, supporting the favorable survival benefits observed previously in patients with a L858R.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。